{"ticker": {"uuid": "f2c9357c-c1a9-4ab4-a83d-ea4b83c7336d", "symbol": "IMA", "name": "ImageneBio, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ImageneBio, Inc. Financial Disclosures & SEC Filings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1uTkRFZTVJSnNpSDhRSWNwam5qTV9GVzUtZ2QtZ3l6cTFFZnk1TVNheUNUN1ZXNC14cm00ZVhkNHpEd0lCUFdkMDVVSmdtTnQ2MVBCWi1rUGpLajVZdkhwb2U1Wk1tMndv?oc=5", "source_name": "TradingView", "published_at": "2026-07-19T03:07:20+00:00", "published_display": "19 Jul 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of ImageneBio, Inc. \u2013 NASDAQ:IMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVXJGaWJ1RDViTmtwZGw0WE4ySTFfMVhacGpqRVZWZE4xXzBRYkRNRGF1TVZpSkVzNDczZjJUQl95dkk4SXFXSDVZUXBSanAtZXc5enFXcHVSR2tzaTdYaEx2QzZQMzF0QXNMQkozSG9YUG9kTF9QeVRjZzY1VHRIOENwS2tpNTJRRjFlcTBCaGxxUmZsNXgwdFNXcGx4S1NGODBzNGEyMTNhbzA?oc=5", "source_name": "TradingView", "published_at": "2026-07-07T10:44:06+00:00", "published_display": "07 Jul 2026 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImageneBio (NASDAQ:IMA) Rating Lowered to Sell at Wall Street Zen", "summary": "Wall Street Zen has downgraded ImageneBio (NASDAQ:IMA) from a \"hold\" to a \"sell\" rating due to a more bearish outlook on the biotech stock. This decision follows the company's recent quarterly earnings report, where it posted a wider-than-expected loss of -$0.95 EPS, significantl", "url": "https://www.marketbeat.com/instant-alerts/imagenebio-nasdaqima-rating-lowered-to-sell-at-wall-street-zen-2026-05-09/", "source_name": "MarketBeat", "published_at": "2026-05-11T06:10:55", "published_display": "11 May 2026 06:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio (NASDAQ: IMA) plans 2026 virtual meeting and equity plan vote", "summary": "ImageneBio (NASDAQ: IMA) has announced its 2026 virtual Annual Meeting of Stockholders for June 16, 2026. Shareholders will vote on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and the approval of an a", "url": "https://www.stocktitan.net/sec-filings/IMA/def-14a-imagene-bio-inc-definitive-proxy-statement-c0876b2b045b.html", "source_name": "Stock Titan", "published_at": "2026-04-30T21:10:17", "published_display": "30 Apr 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImageneBio, Inc. Secures $30 Million in Private Placement Led by Coastlands Capital to Advance IMG-007 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPYW5JNEJrYm9zM1JSNXhfbjV1ZGRZbDVFRnh5eEFEWm95S3NTcjR5c2hRNEw3ME9zczNJRWhVNDQ3UXk0SlZTMjU4X3NISFY4M1Q1NFliMExoRHhyVXJRUTNaZ2p0TUhidnIxUWZ1bm54S3JBMjB0T1Z5eEh6YnVfMnlINEN1aDVqSWpIRU5mMEVzRTZUUkhfcnlzMkoyWG42ZDFFM1hxdHQxNXZCWG9iS1JwWnM3RzFEUFdIWTJaN080ZjRCZElkUVdyeGpFU1BfNjA3WTE5cC1XZFdrNzR2cENpdk1Odw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ikena Oncology Inc Stock: Navigating Biotechnology Innovation Amid Recent Reverse Split and Symbol C", "summary": "Ikena Oncology Inc (ISIN: US4517401090), a clinical-stage precision oncology company, recently executed a 1-for-12 reverse stock split and symbol change to IMA, reshaping its market position for North American investors focused on targeted cancer therapies. The company is develop", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ikena-oncology-inc-stock-navigating-biotechnology-innovation-amid-recent/69048064", "source_name": "AD HOC NEWS", "published_at": "2026-04-01T14:33:01", "published_display": "01 Apr 2026 14:33", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ikena Oncology Inc Stock: Navigating Biotechnology Innovation Amid Recent Reverse Split and Symbol Change", "summary": "Ikena Oncology Inc recently underwent a 1-for-12 reverse stock split and symbol change to IMA, aiming to enhance its market position for North American investors. The clinical-stage precision oncology company, which specializes in small molecule therapeutics for hard-to-treat can", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/ikena-oncology-inc-stock-navigating-biotechnology-innovation-amid-recent/69048064", "source_name": "AD HOC NEWS", "published_at": "2026-04-01T12:10:51", "published_display": "01 Apr 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs", "summary": "ImageneBio, Inc. announced a mutual separation with its Senior Vice President, Finance & Administration and Principal Accounting Officer, Erin Butler, effective March 20, 2026. Bob Lally, currently Senior Vice President, Finance & Operations, has been appointed as her successor f", "url": "https://www.stocktitan.net/sec-filings/IMA/8-k-imagene-bio-inc-reports-material-event-361adea49cb9.html", "source_name": "Stock Titan", "published_at": "2026-03-17T20:09:00", "published_display": "17 Mar 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update", "summary": "ImageneBio, Inc. reported its financial results for Q4 and full year 2025, highlighting the ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis with promising early safety data and a topline readout expected in 2027. The company also announced key executive hires and", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMA/pressreleases/661351/imagenebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update/", "source_name": "The Globe and Mail", "published_at": "2026-03-12T15:40:24", "published_display": "12 Mar 2026 15:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Ikena Oncology, Inc. Insider Trading Activity", "summary": "This article details an insider trading Form 4 filing for Ikena Oncology, Inc. (now ImageneBio, Inc.) by director Stampacchia Otello. The filing indicates a net purchase of 267,556 shares valued at approximately $8 million on July 25, 2025, primarily through Omega Fund VI, L.P. T", "url": "https://www.stocktitan.net/sec-filings/IKNA/form-4-ikena-oncology-inc-insider-trading-activity-e5b0bfbe306b.html", "source_name": "Stock Titan", "published_at": "2025-07-30T04:47:00", "published_display": "30 Jul 2025 04:47", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMA Stock Price and Chart \u2014 NASDAQ:IMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE1pZWhxMVVIMzRVdXJxZ1REdDk3RkxLT2VTQTBubDVZVjluUDdUd1hhNWlkMXBHdGJicVVheGx3d2NCSG1CX0RUZlFJVmtlTHc1YUM1cFR2WFF0R0E?oc=5", "source_name": "TradingView", "published_at": "2025-07-28T13:52:48+00:00", "published_display": "28 Jul 2025 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ImageneBio, Inc. Financial Disclosures & SEC Filings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1uTkRFZTVJSnNpSDhRSWNwam5qTV9GVzUtZ2QtZ3l6cTFFZnk1TVNheUNUN1ZXNC14cm00ZVhkNHpEd0lCUFdkMDVVSmdtTnQ2MVBCWi1rUGpLajVZdkhwb2U1Wk1tMndv?oc=5", "source_name": "TradingView", "published_at": "2026-07-19T03:07:20+00:00", "published_display": "19 Jul 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ImageneBio, Inc. \u2013 NASDAQ:IMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVXJGaWJ1RDViTmtwZGw0WE4ySTFfMVhacGpqRVZWZE4xXzBRYkRNRGF1TVZpSkVzNDczZjJUQl95dkk4SXFXSDVZUXBSanAtZXc5enFXcHVSR2tzaTdYaEx2QzZQMzF0QXNMQkozSG9YUG9kTF9QeVRjZzY1VHRIOENwS2tpNTJRRjFlcTBCaGxxUmZsNXgwdFNXcGx4S1NGODBzNGEyMTNhbzA?oc=5", "source_name": "TradingView", "published_at": "2026-07-07T10:44:06+00:00", "published_display": "07 Jul 2026 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio (NASDAQ:IMA) Rating Lowered to Sell at Wall Street Zen", "summary": "Wall Street Zen has downgraded ImageneBio (NASDAQ:IMA) from a \"hold\" to a \"sell\" rating due to a more bearish outlook on the biotech stock. This decision follows the company's recent quarterly earnings report, where it posted a wider-than-expected loss of -$0.95 EPS, significantl", "url": "https://www.marketbeat.com/instant-alerts/imagenebio-nasdaqima-rating-lowered-to-sell-at-wall-street-zen-2026-05-09/", "source_name": "MarketBeat", "published_at": "2026-05-11T06:10:55", "published_display": "11 May 2026 06:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio (NASDAQ: IMA) plans 2026 virtual meeting and equity plan vote", "summary": "ImageneBio (NASDAQ: IMA) has announced its 2026 virtual Annual Meeting of Stockholders for June 16, 2026. Shareholders will vote on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and the approval of an a", "url": "https://www.stocktitan.net/sec-filings/IMA/def-14a-imagene-bio-inc-definitive-proxy-statement-c0876b2b045b.html", "source_name": "Stock Titan", "published_at": "2026-04-30T21:10:17", "published_display": "30 Apr 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio, Inc. Secures $30 Million in Private Placement Led by Coastlands Capital to Advance IMG-007 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPYW5JNEJrYm9zM1JSNXhfbjV1ZGRZbDVFRnh5eEFEWm95S3NTcjR5c2hRNEw3ME9zczNJRWhVNDQ3UXk0SlZTMjU4X3NISFY4M1Q1NFliMExoRHhyVXJRUTNaZ2p0TUhidnIxUWZ1bm54S3JBMjB0T1Z5eEh6YnVfMnlINEN1aDVqSWpIRU5mMEVzRTZUUkhfcnlzMkoyWG42ZDFFM1hxdHQxNXZCWG9iS1JwWnM3RzFEUFdIWTJaN080ZjRCZElkUVdyeGpFU1BfNjA3WTE5cC1XZFdrNzR2cENpdk1Odw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ikena Oncology Inc Stock: Navigating Biotechnology Innovation Amid Recent Reverse Split and Symbol C", "summary": "Ikena Oncology Inc (ISIN: US4517401090), a clinical-stage precision oncology company, recently executed a 1-for-12 reverse stock split and symbol change to IMA, reshaping its market position for North American investors focused on targeted cancer therapies. The company is develop", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ikena-oncology-inc-stock-navigating-biotechnology-innovation-amid-recent/69048064", "source_name": "AD HOC NEWS", "published_at": "2026-04-01T14:33:01", "published_display": "01 Apr 2026 14:33", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ikena Oncology Inc Stock: Navigating Biotechnology Innovation Amid Recent Reverse Split and Symbol Change", "summary": "Ikena Oncology Inc recently underwent a 1-for-12 reverse stock split and symbol change to IMA, aiming to enhance its market position for North American investors. The clinical-stage precision oncology company, which specializes in small molecule therapeutics for hard-to-treat can", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/ikena-oncology-inc-stock-navigating-biotechnology-innovation-amid-recent/69048064", "source_name": "AD HOC NEWS", "published_at": "2026-04-01T12:10:51", "published_display": "01 Apr 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs", "summary": "ImageneBio, Inc. announced a mutual separation with its Senior Vice President, Finance & Administration and Principal Accounting Officer, Erin Butler, effective March 20, 2026. Bob Lally, currently Senior Vice President, Finance & Operations, has been appointed as her successor f", "url": "https://www.stocktitan.net/sec-filings/IMA/8-k-imagene-bio-inc-reports-material-event-361adea49cb9.html", "source_name": "Stock Titan", "published_at": "2026-03-17T20:09:00", "published_display": "17 Mar 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update", "summary": "ImageneBio, Inc. reported its financial results for Q4 and full year 2025, highlighting the ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis with promising early safety data and a topline readout expected in 2027. The company also announced key executive hires and", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMA/pressreleases/661351/imagenebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update/", "source_name": "The Globe and Mail", "published_at": "2026-03-12T15:40:24", "published_display": "12 Mar 2026 15:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Ikena Oncology, Inc. Insider Trading Activity", "summary": "This article details an insider trading Form 4 filing for Ikena Oncology, Inc. (now ImageneBio, Inc.) by director Stampacchia Otello. The filing indicates a net purchase of 267,556 shares valued at approximately $8 million on July 25, 2025, primarily through Omega Fund VI, L.P. T", "url": "https://www.stocktitan.net/sec-filings/IKNA/form-4-ikena-oncology-inc-insider-trading-activity-e5b0bfbe306b.html", "source_name": "Stock Titan", "published_at": "2025-07-30T04:47:00", "published_display": "30 Jul 2025 04:47", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMA Stock Price and Chart \u2014 NASDAQ:IMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE1pZWhxMVVIMzRVdXJxZ1REdDk3RkxLT2VTQTBubDVZVjluUDdUd1hhNWlkMXBHdGJicVVheGx3d2NCSG1CX0RUZlFJVmtlTHc1YUM1cFR2WFF0R0E?oc=5", "source_name": "TradingView", "published_at": "2025-07-28T13:52:48+00:00", "published_display": "28 Jul 2025 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 20, "sentiment_summary": {"positive": 5, "negative": 2, "neutral": 13, "score": 54, "total": 20, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 79, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "general", "label": "Market update", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 5.38, "latest_week": "2026-07-17", "one_week_move": -9.0, "four_week_move": -10.3, "twelve_week_move": -5.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.38503, "market_dynamics_buy_signal": false, "relative_strength": -37.649025, "fair_value_gap": -70.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.556, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.0% over one week, -10.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "AD HOC NEWS", "count": 2}, {"label": "MarketBeat", "count": 1}, {"label": "Quiver Quantitative", "count": 1}, {"label": "The Globe and Mail", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 11}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 12}, {"label": "Market update", "count": 7}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "11", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.0% over one week, -10.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ImageneBio, Inc. Financial Disclosures & SEC Filings"}], "updated_at": "2026-07-22T08:08:40.770402+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}